ZA200308638B - 4(Phenyl-piperazinyl-methyl)benzamide derivatives and their use for the treatment of pain anxiety or gastrointestinal disorders. - Google Patents
4(Phenyl-piperazinyl-methyl)benzamide derivatives and their use for the treatment of pain anxiety or gastrointestinal disorders. Download PDFInfo
- Publication number
- ZA200308638B ZA200308638B ZA200308638A ZA200308638A ZA200308638B ZA 200308638 B ZA200308638 B ZA 200308638B ZA 200308638 A ZA200308638 A ZA 200308638A ZA 200308638 A ZA200308638 A ZA 200308638A ZA 200308638 B ZA200308638 B ZA 200308638B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- formula
- methyl
- phenyl
- treatment
- Prior art date
Links
- 230000036407 pain Effects 0.000 title claims description 11
- 208000002193 Pain Diseases 0.000 title claims description 10
- 208000018522 Gastrointestinal disease Diseases 0.000 title claims description 8
- 208000019901 Anxiety disease Diseases 0.000 title claims description 5
- 230000036506 anxiety Effects 0.000 title claims description 5
- 150000003936 benzamides Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 77
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 37
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 125000001153 fluoro group Chemical group F* 0.000 claims description 12
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 11
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 claims description 10
- 125000002541 furyl group Chemical group 0.000 claims description 9
- 125000002883 imidazolyl group Chemical group 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 9
- 125000001544 thienyl group Chemical group 0.000 claims description 9
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 8
- -1 4-benzyl-1-piperazinyl Chemical group 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 230000004224 protection Effects 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 125000001246 bromo group Chemical group Br* 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 125000002346 iodo group Chemical group I* 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 208000027520 Somatoform disease Diseases 0.000 claims description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 3
- 208000027753 pain disease Diseases 0.000 claims description 3
- 229910015845 BBr3 Inorganic materials 0.000 claims description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims description 2
- 238000003776 cleavage reaction Methods 0.000 claims description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 230000007017 scission Effects 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 8
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 claims 1
- AQJCXKVOPRUSOL-UHFFFAOYSA-N 4-[(3-aminophenyl)-(4-benzylpiperazin-1-yl)methyl]-n,n-diethylbenzamide Chemical compound C1=CC(C(=O)N(CC)CC)=CC=C1C(C=1C=C(N)C=CC=1)N1CCN(CC=2C=CC=CC=2)CC1 AQJCXKVOPRUSOL-UHFFFAOYSA-N 0.000 claims 1
- NZXYDHJFJFWXKL-UHFFFAOYSA-N 4-[(3-aminophenyl)-[4-(thiophen-3-ylmethyl)piperazin-1-yl]methyl]-n,n-di(propan-2-yl)benzamide Chemical compound C1=CC(C(=O)N(C(C)C)C(C)C)=CC=C1C(C=1C=C(N)C=CC=1)N1CCN(CC2=CSC=C2)CC1 NZXYDHJFJFWXKL-UHFFFAOYSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 208000014540 Functional gastrointestinal disease Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 150000001860 citric acid derivatives Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- 229910004373 HOAc Inorganic materials 0.000 description 8
- 239000012458 free base Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000000556 agonist Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 4
- 239000000730 antalgic agent Substances 0.000 description 4
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 3
- RBIGKSZIQCTIJF-UHFFFAOYSA-N 3-formylthiophene Chemical compound O=CC=1C=CSC=1 RBIGKSZIQCTIJF-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102000003840 Opioid Receptors Human genes 0.000 description 2
- 108090000137 Opioid Receptors Proteins 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000001949 anaesthesia Methods 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- HFHFGHLXUCOHLN-UHFFFAOYSA-N 2-fluorophenol Chemical class OC1=CC=CC=C1F HFHFGHLXUCOHLN-UHFFFAOYSA-N 0.000 description 1
- AZVSIHIBYRHSLB-UHFFFAOYSA-N 3-furaldehyde Chemical compound O=CC=1C=COC=1 AZVSIHIBYRHSLB-UHFFFAOYSA-N 0.000 description 1
- ZETIVVHRRQLWFW-UHFFFAOYSA-N 3-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=CC(C=O)=C1 ZETIVVHRRQLWFW-UHFFFAOYSA-N 0.000 description 1
- HTLHMIALIFKABS-UHFFFAOYSA-N 4-[(3-aminophenyl)-(4-benzylpiperazin-1-yl)methyl]-n,n-di(propan-2-yl)benzamide Chemical compound C1=CC(C(=O)N(C(C)C)C(C)C)=CC=C1C(C=1C=C(N)C=CC=1)N1CCN(CC=2C=CC=CC=2)CC1 HTLHMIALIFKABS-UHFFFAOYSA-N 0.000 description 1
- MNUZJZQILRFDRM-UHFFFAOYSA-N 4-[(4-benzylpiperazin-1-yl)-(4-fluoro-3-hydroxyphenyl)methyl]-n,n-di(propan-2-yl)benzamide Chemical compound C1=CC(C(=O)N(C(C)C)C(C)C)=CC=C1C(C=1C=C(O)C(F)=CC=1)N1CCN(CC=2C=CC=CC=2)CC1 MNUZJZQILRFDRM-UHFFFAOYSA-N 0.000 description 1
- DCZPTCGNXVKMTI-UHFFFAOYSA-N 4-[(4-fluoro-3-hydroxyphenyl)-[4-(thiophen-3-ylmethyl)piperazin-1-yl]methyl]-n,n-di(propan-2-yl)benzamide Chemical compound C1=CC(C(=O)N(C(C)C)C(C)C)=CC=C1C(C=1C=C(O)C(F)=CC=1)N1CCN(CC2=CSC=C2)CC1 DCZPTCGNXVKMTI-UHFFFAOYSA-N 0.000 description 1
- KQWVAUSXZDRQPZ-UMTXDNHDSA-N 4-[(R)-[(2S,5R)-2,5-dimethyl-4-prop-2-enyl-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide Chemical group C1=CC(C(=O)N(CC)CC)=CC=C1[C@H](C=1C=C(OC)C=CC=1)N1[C@@H](C)CN(CC=C)[C@H](C)C1 KQWVAUSXZDRQPZ-UMTXDNHDSA-N 0.000 description 1
- AKCMIUUHQWRJRW-UHFFFAOYSA-N 4-[[3-(methanesulfonamido)phenyl]-[4-(thiophen-3-ylmethyl)piperazin-1-yl]methyl]-n,n-di(propan-2-yl)benzamide Chemical compound C1=CC(C(=O)N(C(C)C)C(C)C)=CC=C1C(C=1C=C(NS(C)(=O)=O)C=CC=1)N1CCN(CC2=CSC=C2)CC1 AKCMIUUHQWRJRW-UHFFFAOYSA-N 0.000 description 1
- NALVGTOMKSKFFV-UHFFFAOYSA-N 4-fluoro-3-methoxybenzaldehyde Chemical compound COC1=CC(C=O)=CC=C1F NALVGTOMKSKFFV-UHFFFAOYSA-N 0.000 description 1
- YTDOXNTWNWFWPG-UHFFFAOYSA-N 4-iodo-n,n-di(propan-2-yl)benzamide Chemical compound CC(C)N(C(C)C)C(=O)C1=CC=C(I)C=C1 YTDOXNTWNWFWPG-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 208000020339 Spinal injury Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 229940124326 anaesthetic agent Drugs 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 230000005961 cardioprotection Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 239000000842 neuromuscular blocking agent Substances 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Description
4(Phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders.
The present invention is directed to novel compounds, to a process for their preparation, . s their use and pharmaceutical compositions comprising the novel compounds. The novel compounds are useful in therapy, and in particular for the treatment of pain, anxiety and functional gastrointestinal disorders.
The 8 receptor has been identified as having a role in many bodily functions such as circulatory and pain systems. Ligands for the d receptor may therefore find potential use as analgesics, and/or as antihypertensive agents. Ligands for the 6 receptor have also been shown to possess immunomodulatory activities.
The identification of at least three different populations of opioid receptors (, 6 and x) is "now well established and all three are apparent in both central and peripheral nervous systems of many species including man. Analgesia has been observed in various animal models when one or more of these receptors has been activated.
With few exceptions, currently available selective opioid J ligands are peptidic in nature and are unsuitable for administration by systemic routes. One example of a non-peptidic
S-agonist is SNC80 (Bilsky E.J. et al., Journal of Pharmacology and Experimental
Therapeutics, 273(1), pp. 359-366 (1995)). There is however still a need for selective
S-agonists having not only improved selectivity, but also an improved side-effect profile. . Thus, the problem underlying the present invention was to find new analgesics having improved analgesic effects, but also with an improved side-effect profile over current 1 ) agonists, as well as having improved systemic efficacy.
Analgesics that have been identified and are existing in the prior art have many disadvantages in that they suffer from poor pharmacokinetics and are not analgesic when administered by systemic routes. Also, it has been documented that preferred & agonist . compounds, described within the prior art, show significant convulsive effects when administered systemically. :
We have now found certain compounds that exhibit surprisingly improved properties, i.a. improved 8-agonist potency, in vivo potency, pharmacokinetic, bioavailability, in vitro stability and/or lower toxicity.
Outline of the Invention
The novel compounds according to the present invention are defined by the formula I 0)
R2 3 ~ R
NOP
R2 R4
N .
N
« wherein rR! is selected from any one of (i) phenyl; (ii) pyridinyl
B® =
N
(111) thienyl
S . (iv) furanyl
Oo (v) imidazolyl
M
\ J \ J : (vi) triazolyl :
WW
N— (vii) pyrrolyl
N
H
(viii) thiazolyl
J
\_J . (ix) pyridyl-N-oxide o ; N
AN
(J wherein each R' heteroaromatic ring may optionally and independently be further substituted by 1, 2 or 3 substituents selected from straight and branched C,-Cg alkyl, halogenated C,-Cs alkyl, NO,, CF3, C,-Cg alkoxy, chloro, fluoro, bromo, and iodo; 5s Ris independently selected from ethyl and isopropyl, .
R® is independently selected from hydrogen and fluoro; : :
R* is independently selected from -OH, -NH, and -NHSO,R’; and
R’ is independently selected from hydrogen, -CF3 and C,-Cg alkyl, provided that when R? is ethyl and R® is hydrogen then R* cannot be -OH.
The substitutions on the heteroaromatic ring may take place in any position on said ring systems.
When the rR! phenyl ring and the R' heteroaromatic ring(s) are substituted, the preferred substituents are selected from any one of CF;, methyl, iodo, bromo, fluoro and chloro, of which methyl is most preferred.
A further embodiment of the present invention is thus a compound according to formula I wherein R' is as defined above and each R! phenyl ring and R! heteroaromatic ring may : independently be further substituted by a methyl group; 2s A further embodiment of the present invention is a compound according to figure I wherein
R'is phenyl, pyrrolyl, furanyl, thienyl or imidazolyl; R* is ethyl or isopropyl; R?is hydrogen or fluoro; R* is -NH, or -NHSO,R; and R® is C,-Cg alkyl, optionally with 1 or 2 of the preferred substituents on the Rr! phenyl or Rr! heteroaromatic ring.
An additional embodiment of the present invention is a compound according to figure 1 wherein R' is phenyl, pyrrolyl, furanyl, thienyl or imidazolyl; R? is ethyl or isopropyl; R?is hydrogen; R* is -NHSO,R?; and R® is C;-Cg alkyl, optionally with 1 or 2 of the preferred substituents on the rR! phenyl or rR! heteroaromatic ring. . Other embodiments of the present invention are compounds according to Figure I wherein a) R'is phenyl, pyrrolyl, or furanyl; R? is ethyl or isopropyl; R? is hydrogen or fluoro; and ‘ 5s R'is -NH,; b) R' is thienyl or imidazolyl; R? is ethyl or isopropyl; Ris hydrogen or fluoro; and R* is -NH,; c)R'is phenyl, pyrrolyl, furanyl, thienyl or imidazolyl; R? is ethyl or isopropyl; R’ is hydrogen or fluoro; R? is -NHSO,R>; and R’ is C;-C alkyl; and d) R' is phenyl, pyrrolyl, furanyl, thienyl or imidazolyl; R? is ethyl or isopropyl; R? is hydrogen or fluoro; R* is -NHSO,R?; and R® is C,-Cg alkyl, wherein all embodiments a) to d) may - optionally be substituted with 1 or 2 of the preferred substituents on the R! phenyl or Rr! heteroaromatic ring. :
Within the scope of the invention are also separate enantiomers and salts of the compounds of the formula 1, including salts of enantiomers. Also within the scope of the present is invention are mixtures of the separate enantiomers, such as the racemic mixuture, as well ~ as salts of mixtures of separate enantiomers. :
Separation of racemic mixtures into separate enantiomers is well known in the art and may be accomplished for example by separation on a suitable chiral chromatography column.
Preparation of salts is well known in the art, and may be accomplished for example by mixing a compound of formula I in a suitable solvent with the desired protic acid and isolation by means standard in the art. Salts of compounds of formula I include pharmaceutically acceptable salts and also pharmaceutically unacceptable salts. 2s The novel compounds of the present invention are useful in therapy, especially for the treatment of various pain conditions such as chronic pain, neuropathic pain, acute pain, : cancer pain, pain caused by rheumatoid arthritis, migraine, visceral pain etc. This list should however not be interpreted as exhaustive.
Compounds of the invention are useful as immunomodulators, especially for autoimmune diseases, such as arthritis, for skin grafts, organ transplants and similar surgical needs, for collagen diseases, various allergies, for use as anti-tumour agents and anti viral agents. : 5s Compounds of the invention are useful in disease states where degeneration or dysfunction ) of opioid receptors is present or implicated in that paradigm. This may involve the use of isotopically labelled versions of the compounds of the invention in diagnostic techniques and imaging applications such as positron emission tomography (PET). oo
Compounds of the invention are useful for the treatment of diarrhoea, depression, anxiety and stress-related disorders such as post-traumatic stress disorders, panic disorder, : generalized anxiety disorder, social phobia, and obesessive compulsive disorder; urinary incontinence, various mental illnesses, cough, lung oedema, various gastro-intestinal disorders, e.g. constipation, functional gastrointestinal disorders such as Irritable Bowel
Syndrome and Functional Dyspepsia, Parkinson's disease and other motor disorders, traumatic brain injury, stroke, cardioprotection following miocardial infarction, spinal injury and drug addiction, including the treatment of alcohol, nicotine, opioid and other drug abuse and for disorders of the sympathetic nervous system for example hypertension.
Compounds of the invention are useful as an analgesic agent for use during general anaesthesia and monitored anaesthesia care. Combinations of agents with different properties are often used to achieve a balance of effects needed to maintain the anaesthetic state (e.g. amnesia, analgesia, muscle relaxation and sedation). Included in this combination are inhaled anaesthetics, hypnotics, anxiolytics, neuromuscular blockers and opioids.
Also within the scope of the invention is the use of any of the compounds according to the formula I above, for the manufacture of a medicament for the treatment of any of the conditions discussed above.
A further aspect of the invention is a method for the treatment of a subject suffering from any of the conditions discussed above, whereby an effective amount of a compound : according to the formula I above, is administered to a patient in need of such treatment. ‘ 5 Methods of preparation
The compounds of the present invention can be prepared using the following general procedure.
Preparation of Phenols; Examples 1-3
The compounds of formula I wherein R* is —OH is prepared by reacting a compound of the general formula II : 0]
R2 3 ~N R
NSPS
© R2 Re
Br ii wherein R* and R are as defined in Figure 1 and R* is OMe, with Boc-piperazine in acetonitrile in the presence of triethylamine under standard conditions, followed by removal of the Boc protection group under standard conditions to give a compound of the
Formula II :
Oo
R2_ \ R3 : : R2 OMe 0)
N
H 0 which is thereafter alkylated under reductive conditions with a compound of the Formula
R'-CHO, followed by cleavage of the methyl ether using BBr3 in dichloromethane to give a compound of the Formula I wherein R* is -OH. i
Preparation of Anilines; Examples 4-6 >
The compound of formula I wherein R*is NH, is prepared by reacting a compound of the general formula IV
Oo :
R2 R3
Tod
R? R4 CL
Br Vv wherein R? and R® are as defined in Figure 1 and R* is NO», with Boc-piperazine in + acetonitrile in the presence of triethylamine under standard conditions, followed by removal of the Boc protection group under standard conditions to give a compound of the
Formula V 5
RN R3 ke
NO, ®
N
H Vv : which is thereafter alkylated under reductive conditions with a compound of the Formula :
R'-CHO, followed by reduction of the nitro group using hydrogen and palladium on charcoal to give a compound of the Formula I wherein R* is -NH,.
Preparation of Methyl Sulfonanilides; Examples 7-8
The compound of formula I wherein R* is -NHSO,R® is prepared by reacting a compound . of the general formula VI
Oo
R? R3
TC QO
R? Rs
Br VI wherein R? and R® are as defined in claim 1 and R*is NO, with Boc-piperazine in acetonitrile in the presence of triethylamine under standard conditions, followed reduction of the nitro group by hydrogenolysis using palladium on charcoal as the catalyst, metanesulphonylation using methanesulphonylanhydride in dichloromethane in the presence of triethylamine, and thereafter removal of the Boc protection group under standard conditions to give a compound of the Formula VII : 0 : ™ SUSHI
Re NHSO,CH, 0)
N
H Ai which is thereafter alkylated under reductive conditions with a compound of the Formula ©
R'-CHO, followed by reduction of the nitro group using hydrogen and palladium on charcoal to give a compound of the Formula I wherein R* is -NHSO,R”.
Within the scope of the invention are also separate enantiomers and salts of the compounds of the Formula I, including salts of enantiomers. Compounds of Formula I are chiral compounds, with the diarylmethylpiperazine group being the stereogenic center, see Figure
I* below. oO
R2 3 ~N R
NOE
* ©
R? R4 . _N :
N
«
A further embodiment of the present invention is thus the (-)-enantiomer of a compound according to Formula I, as well as a salt of said compound.
A further embodiment of the present invention is thus the (+)-enantiomer of a compound according to Formula I, as well as a salt of said compound.
The invention will now be described in more detail by the following Examples, which are not to be construed as limiting the invention.
Scheme 1: Preparation of Fluoro Phenols; Examples 1-3 ey OL om
H AL ep— PN o SOB, CHC < i 2) Boc-piperazine, 3) TFA, CH,Cl, (81%)
Oo o ’ PR F
A Qeee
N
TOC eo on . 0 N 1. 1)BnBr, TEA, ACN
N CH; 2) BBr,, CH,C, (50%) (2 C ) N
N of Example 1 . _H : 1) thiophene-3-carboxaldehyde,
NaBH,CH, MeOH, HOAc 1) imidazole-2-carboxaldehyde, 2) BBr,, CH,Cl,, 26% NaBH,CN, MeOH, HOAc : 2) BBr,, CH,Cl,, 25% . I °
A OH A OH
0) | 0)
SN N
- os E
S B xample 2 « N Example 3
Intermediate 1: 4-] (4-fluoro-3-methoxyphenyl )(hydroxy)methyl]-N,N-diisopropyl- benzamide.
N,N-Diisopropyl-4-iodobenzamide (6.0 g, 18 mmol) was dissolved in THF (200 mL) and cooled to -78 °C under nitrogen atmosphere. n-BuLi (14 mL, 1.3 M solution in hexane, 18 : mmol) was added dropwise during 10 min at -65 to -78 °C. 4-fluoro-3- methoxybenzaldehyde (2.8 g, 18 mmol) was added dropwise dissolved in THF (5 mL). ) NH,Cl (aq.) was added after 30 min. After concentration in vacuo, extraction with EtOAc / water, drying (MgSO4) and evaporation of the organic phase, the residue was purified by chromatography on silica (0 — 75% EtOAc/heptane) to yield the desired product (3.9 g, ’
60%)."H NMR ( CDCl3) 8 1.0-1.6 (m, 12H), 2.65 (d, J = 4Hz, 1H), 3.4-3.9 (m, 2H), 3.80 (s, 3H), 6.10 (d, J = 4Hz, 1H), 6.76 (m, 1H), 6.95 (m, 1H), 7.04 (m, 1H), 6.76 (m, 1H), 7.25, 7.40 (24, J = 7.5Hz, 4H). : 5s Intermediate 2: 4-[(4-fluoro-3-methoxyphenyl)( I-piperazinyl)methyl]-N.N- diisopropylbenzamide.
Intermediate 1 (3.9 g, 11 mmol) was dissolved in dry CH,Cl; (50 mL) and treated with
SOB, (0.88 mL, 11 mmol) at 0 to 25 °C for 30 min. Neutralization with KHCO, (aq.) and drying (K2COs) of the organic phase was followed by solvent evaporation in vacuo. The residue and EN (1.8 mL, 13 mmol) was dissolved in MeCN (50 mL) and stirred with
Boc-piperazine (2.1 g, 11 mmol) at 25 °C for 12 h. Concentration in vacuo and ~~. chromatography on silica (0 to 50% EtOAc in heptane) gave 4.6g. 1.6g was treated with
TFA in CH,Cl; (1:1), concentrated in vacuo, extracted CH,Cly/ K2CO4 (aq.), dried (K:CO.) and evaporated in vacuo to give Intermediate 2 (1.3 g, 81% from intermediate 1).
MS (ES) 428.21 (MH+).
Example 1: 4-[1-(4-Benzyl-piperazin-1-yl)-1-(4-fluoro-3-hydroxy-phenyl }-methyl]-N,N- diisopropyl-benzamide.
Intermediate 2 (0.41 g, 0.96 mmol) and triethylamine (0.20 mL, 1.4 mmol) were dissolved 2 in MeCN (10 mL). Benzyl bromide (0.14 mL, 1.1 mmol) was added with stirring at 25 °C.
After 12 h the solution was concentrated and purified by reverse phase chromatography (LiChroprep RP-18, 10-80 % MeCN in water, 0.1 % TFA). 0.53 g of free base was obtained after extraction with CH,Cly/ K,COj4 (aq.), drying (K2COs) and evaporation in vacuo. Treatment with boron tribromide ( 4 eq., IM solution in CH,Cl,) in CHCl, at —78 °C, addition of water, concentration in vacuo and reverse phase chromatography gave
Example 1 as the trifluoroacetate (0.35 g, 50%). MS (ES) 504.22 (MH+). IR (NaCl) 3222, 1677, 1592, 1454, 1346, 1201, 1135 (cm-1). '"H NMR (CD;0D) § = 1.1, 1.5 (m, 12H), 2.3 (m, 3H), 2.9-3.8 (m, 7H), 4.33 (s, 2H), 4.75 (s, 1H), 6.60 (m, 1H), 6.83 (m, 1H), 6.94 (m, 1H), 7.24 (d, J = 8 Hz, 2H), 7.47 (m, 7TH). Anal. Calc. for C3;H3sFN302 x0.8C4HoFsO4 .
C:59.87,H:5.82,N:6.12. Found C:60.06, H:5.83, N:6.19. :
Example 2: 4-[1-(4-Fluoro-3-hydroxy-phenyl)-1-(4-thiophen-3-ylmethyl-piperazin-1-yl)- methyl]-N, N-diisopropyl-benzamide.
Intermediate 2 (0.43 g, 1.0 mmol) was dissolved in MeOH (5 mL) with 3-thiophene- } 5 carboxaldehyde (0.11 mL, 1.2 mmol) and HOAc (57 pL, 1.0 mmol) and stirred for 1 h.
Sodium cyanoborohydride (63 mg, 1.0 mmol) was added in portions over 6 h and the reaction was stirred at 25 °C for an additional 12 h before working up by concentration ir vacuo and extraction (CHCl, /K2COj3(aq)). Purification by reverse phase chromatography as for Example 1 to give 0.32 g (0.62 mmol) as free base. Treatment with boron tribromide as for Example 1 and chromatography gave Example 2 (0.20 g, 26%) as the . trifluoroacetate. MS (ES) 510.17 (MH+). IR (NaCl) 3281, 1674, 1606, 1454, 1346, 1200, 1135 (cm-1). "TH NMR (CD;0OD) § = 1.1, 1.5 (m, 12H), 2.30 (m, 2H), 2.9-3.7 (m, 10H), R 4.37 (s, 2H), 4.75 (s, 1H), 6.60 (m, 1H), 6.84 (m, 1H), 6.94 (m, 1H), 7.18 (m, 1H), 7.25, 7.48 (2d, J = 8.0Hz, 4H), 7.55 (m, 1H), 7.65 (m, 1H). Anal. Calc. for CoH36FN30,S x0.8 1s C4H,Fs04 x0.5 H,0, C:55.16, H:5.55, N:5.99. Found, C:55.12, H:5.39, N:6.07.
Example 3: 4-{1-(4-Fluoro-3-hydroxy-phenyl)-1-[4-(1H-imidazol-2-ylmethyl)-piperazin-1- : yll-methy1}-N. N-diisopropyl-benzamide.
Employing the same procedure as for Example 2 reaction with 2-imidazole-carboxaldehyde (0.10 g, 1.1 mmol) followed by treatment with boron tribromide (6 eq.) gave Example 3 (0.18 g, 25%) as the trifluoroacetate. MS (ES) 494.23 (MH+). IR (NaCl) 3123, 1673, 1592, 1454, 1350, 1201, 1135 (cm-1). "H NMR (CD;0D) §=1.1, 1.5 (m, 12H), 2.7-3.8 (m, 10H), 3.95 (s, 2H), 5.20 (m, 1H), 6.70 (m, 1H), 6.94 (m, 1H), 7.02 (m, 1H), 7.32, 7.58 (2d, 2s J=8.0Hz, 4H), 7.46 (s, 1H). Anal. Calc. for CasH3FN;O, x1.2 C4HaF604 x0.7 HO,
C:50.51, H:5.14, N:8.98. Found, C:50.44, H:5.18, N:9.11.
Scheme 2: Preparation of Anilines; Examples 4-6
A
=" OL vee
H 4-Pr,NCOPhI PN No. 1) SOBra, CH.Cl,
NO, 2 0 2 2) Boc-piperazine, o oC n-BuLi, THF (37%) OH ACN. TEA (3) 3) TFA, CH,CI, (81%) : . | 0 0 : ) PN . LAC
Pid N )
PN 9g ( c AN NF,
NO, TT > N 1) BnBr, TEA, ACN } - N 2) H,-Pd/C, EtOH, 30% ( ) (4) ) N
N Example 4 1) thiophene-3-carboxaldehyde,
NaBH,CH, MeOH, HOAc 1) imidazole-2-carboxaldehyde, 2) H2-Pd/C, EtOH, 20% NaBH,CN, MeOH, HOAc 2) H2-Pd/C, EtOH, 7%
Pe 0 LL 0
QGUS!
N jqeVel PN NH, 2 0 >) - ~
S BD Example 5 w N Example 6
Intermediate 3: 4-[Thydroxy(3-nitrophenyl)methyl l-N.N-diisopropylbenzamide.
Procedure as for intermediate 1 but after addition of n-BuLi the solution was cannulated into a solution of 3-nitrobenzaldehyde (2.7 g, 18 mmol) in toluene/THF (approx. 1:1, 100 : 5. mL)at-78 °C. Workup and chromatography gave for intermediate 3 (2.4 g, 37%).'H NMR (CDCl) & 1.1-1.7 (m, 12H), 3.90 (d, J = 3.5 Hz, 1H), 3.4-3.9 (m, 2H), 5.91 (5, J =3.5Hz, 1H), 7.27, 7.35 (2d, I = 8Hz, 4H), 7.51 (m, 1H), 7.71 (m, 1H), 8.13 (m, 1H), 8.30 (s, 1H).
Intermediate 4: N.N-diisopropyl-4-[(3-nitrophenyl)(1-piperazinyl)methyllbenzamide.
Employing the same procedure as for intermediate 2, intermediate 3(2.4 g, 6.7 mmol) gave Boc-protected intermediate 4 (2.83 g, 81%). TFA treatment quantitatively gave intermediate 4. MS (ES) 425.23 (MH+).
Example 4: 4-[1-(3-Amino-phenyl)-1-(4-benzyl-piperazin-1-yl)-methyl]-N,N-diisopropyl- benzamide.
Reaction of 7 (0.40 g, 0.94 mmol) with benzyl bromide as for Example 1 was followed by hydrogenation (Hy, 40 psi) with 10% Pd/C (50 mg) in EtOH (25 mL) and 2 N HCI (1.2 mL, 2.4 mmol) for 2 h. Purification by reverse phase chromatography using the same conditions as for Example 1 gave Example 4 (0.20 g, 30%) as the trifluoroacetate. MS (ES) 485.40 (MH+). IR (NaCl) 3414, 1673, 1605, 1455, 1345, 1201, 1134 (cm-1). 'H NMR (CD;0D) § =1.1, 1.5 (m, 12H), 2.3 (m, 2H), 2.9-3.8 (m, 8H), 4.31 (s, 2H), 4.47 (s, 1H), 7.02 (m, 1H), 7.21-7.52 (m, 12H). Anal. Calc. for C3;HsN4O x1.2 C4H,F04 x0.5 H,0, C:56.04,
H:5.70, N:7.30. Found, C:56.06, H:5.67, N:7.41. - Example 5: 4-[1-(3-Amino-phenyl)-1-(4-thiophen-3-yimethyl-piperazin-1-yl )-methyl]-
N,N-diisopropvl-benzamide.
Reaction of intermediate 4 (0.40 g, 0.94 mmol) with 3-thiophene-carboxaldehyde as for example 2 was followed by hydrogenation (H;, 30 psi) with 10% Pd/C (50 mg) in EtOH (25 mL) and 2 N HCI (1.0 mL, 2.0 mmol) for 12 h. Purification by reverse phase chromatography using the same conditions as for Example 1 gave Example 5 (0.13 g, 20%) as the ditrifluoroacetate. MS (ES) 491.28 (MH+). IR (NaCl) 3408, 1673, 1605, 1455, 1345, 1201, 1134 (cm-1). "TH NMR (CD;0D) 6 = 1.1, 1.5 (m, 12H), 2.3 (m, 2H), 2.9-3.8 (m, 8H), 4.35 (s, 2H), 4.44 (s, 1H), 6.98 (m, 1H), 7.16-7.32 (m, 6H), 7.49 (d, J = 8Hz, 2H), 7.55 (m, 1H), 7.64 (m, 1H). Anal. Calc. for C2oH3sN4OS x1.3 C4H,Fs04 x0.6 H,0, C:51.48,
H:5.28, N:7.02. Found, C:51.51, H:5.20, N:7.01.
Example 6: 4-{1-(3-Amino-phenyl)-1-[4-(1H-imidazol-2-ylmethyl)-piperazin-1-vi]- 25s methyl}-N,N-diisopropyl-benzamide.
Employing the same procedure as for Example 2, reaction of intermediate 4 with 2- imidazole-carboxaldehyde (0.10 g, 1.1 mmol) followed by hydrogenation gave Example 6 : (45 mg, 7%) as ditrifluoroacetate salt. MS (ES) 475.30 (MH+). IR (2x TFA, NaCl) 3351, 1674, 1621, 1455, 1349, 1202, 1134 (cm-1). 'H NMR (2x TFA, CD;0D) §=1.1, 1.5 (m, 3 12H), 2.9-3.8 (m, 8H), 4.35 (s, 2H), 4.44 (5, 1H), 6.98 (m, 1H), 7.16-7.32 (m, 6H), 7.49 (d,
J = 8Hz, 2H), 7.55 (m, 1H), 7.64 (m, 1H). Anal. Calc. for C,5sH3sN¢O x1.6 C4HFs04 x0.8
H,0, C:48.39, H:5.05, N:9.84. Found, C:48.43, H:5.06, N:9.85. :
Scheme 3: Preparation of Methyl Sulfonanilides; Examples 7-8
JJ
H. 4-iPr,NCOPhI A NO. 1) SOBr, CHCl :
NO, B i THE (37% 2 2) Boc-piperazine, 0 n-BuLi, THF (37%) OH ACN, TEA (1) 0
A 9
N Py
XK oe LOC
N NO, 1) H,-Pd/C, HOAc, 12 h A NH : 2) (CH;S0,),0, TEA, CH,CI (4a) C ) 3) TFA, CH,Cl,. ’ N SOCH,
N (5)
A N
070 H 1) furan-3-carboxaldehyde, 1) thiophene-3-carboxaldehyde, NaBH,CN, MeOH, HOAc
NaBH,CH, MeOH, HOAc ~ {2) H2-Pd/C, EtOH, 7% . 2) H2-Pd/C, EtOH, 20% 0 PN 0 sqeN o $0,CH, N SO,CH,
Example 7 ( J Example 8 ( )
N N
Intermediate 5: N.N-diisopropyl-4-[{3-[(methylsulfonyl)amino]}phenyl }(1- piperazinylimethyllbenzamide. - s Intermediate 3 gave Boc-protected Intermediate 4 as described for Intermediate 4, above.
Boc-protected Intermediate 4 (1.21 g, 2.3 mmol) was hydrogenated under Hj at 30 psi with 10% Pd/C (150 mg) in AcOH (25 mL) for 12 h. Evaporation in vacuo and extraction with
CH,Cly/ K2CO4 (aq.) gave 1.1 g (2.3 mmol) of the intermediate aniline, which was dissolved in MeCN/CH,Cl; (1:1, 10 mL). Et;N (0.48 mL, 3.4 mmol), then . methanesulponylanhydride (0.41 g, 2.4 mmol) was added at 0 °C. After warming to room temperature the reaction was worked up by extraction CH,Cly/brine. Purification by chromatography on silica (0 — 5% MeOH/ CH,Cl,) gave Boc-protected Intermediate 5 (1.3 g, 97%). Treatment with TFA in CH,Cl, quantitatively gave Intermediate 5. MS (ES) 473.16 (MH).
Example 7: N,N-Diisopropyl-4-[1-(3-methanesulfonylamino-phenyl)-1-(4-thiophen-3- ylmethyl-piperazin-1-yl)-methyl]-benzamide.
Reductive amination procedure as for Example 2. Intermediate 5 (0.20 g, 0.43 mmol) gave . 5s Example 7 (90 mg, 26%) as ditrifluoroacetate salt. The dihydrochloride salt was obtained after extraction of the free base with CH,Cly/ K,COy4 (aq.) and treatment with 2 eq. HCI (aq.). MS (ES) 569.21 (MH+). IR (free base, NaCl) 1604, 1455, 1340, 1151 (cm-1). 'H
NMR (free base, CDCl3) 6 = 0.9- 1.7 (m, 12H), 2.5 (m, 8H), 2.85 (s, 3H), 3.55 (s, 2H), 3.8 (m, 2H), 4.22 (s, 1H), 7.00-7.40 (m, 12H). Anal. Calc. for C30HN4O3S; x2.6 HCI,
C:54.30, H:6.47, N:8.44. Found, C:54.33, H:6.20, N:8.32.
Example 8: 4-({4-(3-furylmethyl)-1-piperazimyl}{3-[(methyisulfonyl)aminolphenyl }-N,N- diisopropyl-benzamide.
Employing the same procedure as for Intermediate 7. Intermediate 5 (0.21 g, 0.45 mmol) gave Example 8 (80 mg, 32%) as free base. MS (ES) 553.23 (MH+). IR (free base, NaCl) 1604, 1455, 1340, 1151 (cm-1). "H NMR (free base, CDCl3) § = 1.0- 2.6 (m, 20H), 2.91 (s, 3H), 3.40 (s, 2H), 4.22 (s, 1H), 6.39 (s, 1H), 7.06-7.42 (m, 11H). Anal. Calc. for
C30H40N404S x2.8 HCI, C:55.03, H:6.59, N:8.56. Found, C:54.93, H:5.93, N:8.49.
Claims (2)
1. A compound of the formula I : LJ (0) . "R2 R3 ToCoLQ R2 RA N N™ A wherein rR is selected from any one of (i) phenyl; (ii) pyridinyl ~N Pr N i5 (iii) thienyl
Ss .
(iv) furanyl OF (v) imidazolyl H (J \_/ (vi) triazolyl N N—"
(vii) pyrrolyl N H (viii) thiazolyl S (J N (ix) pyridyl-N-oxide 0 N ES [J wherein each R' heteroaromatic ring may optionally and independently be further substituted . by 1, 2 or 3 substituents selected from straight and branched C;-Cs alkyl, halogenated C;-Cg alkyl, NO,, CF3, C;-Cg alkoxy, chloro, fluoro, bromo, and iodo;
C31 Ris independently selected from ethyl and isopropyl; . R’ is independently selected from hydrogen and fluoro; * 5s R'is independently selected from -OH, -NH, and -NHSO,R?; and Ris independently selected from hydrogen, -CF3 and C,-C alkyl, or salts thereof or separate enantiomers and salts thereof, provided that when R? is ethyl and R? is hydrogen then R* cannot be -OH.
© 2. A compound according to claim 1, wherein R' is phenyl, pyrrolyl, furanyl, thienyl or imidazolyl; R? is ethyl or isopropyl; R?is hydrogen or fluoro; R* is -NH, or -NHSO,R?; and RS is C;-Ce alkyl.
3. A compound according to claim 1, wherein R! is phenyl, pyrrolyl, furanyl, thienyl or imidazolyl; R? is ethyl or isopropyl; R? is hydrogen; R* is -NHSO,R’; and R® is C;-C; alkyl.
4. A compound according to claim 1, wherein the heteroaromatic ring(s) are substituted by CF3, methyl, iodo, bromo, fluoro or chloro. | . :
5. A compound according to claim 1, wherein the heteroaromatic ring(s) are substituted by methyl.
6. A compound according to claim 1, selected from any one of 4-[1-(4-Benzyl-piperazin-1-yl)-1-(4-fluoro-3-hydroxy-phenyl)-methyl}-N, N-diisopropyl- benzamide; 4-[1-(4-Fluoro-3-hydroxy-phenyl)-1-(4-thiophen-3-ylmethyl-piperazin-1-yl)-methyl}-N, N- diisopropyl-benzamide; 4-{1-(4-Fluoro-3-hydroxy-phenyl)-1-[4-(1H-imidazol-2-ylmethyl)-piperazin-1-yl}-methyl } - N,N-diisopropyl-benzamide; 4-[1-(3-Amino-phenyl)-1-(4-benzyl-piperazin-1-yl)-methyl}-N,N-diisopropyl-benzamide;
4-[1-(3-Amino-phenyl)- 1-(4-thiophen-3-ylmethyl-piperazin-1-yl)-methyl]-N, N-diisopropyl- benzamide; 4-{1-(3-Amino-phenyl)-1-{4-(1H-imidazol-2-ylmethyl)-piperazin-1-yl]-methyl }-N, N- diisopropyl-benzamide; N,N-Diisopropyl-4-[1-(3-methanesulfonylamino-phenyl)-1-(4-thiophen-3-ylmethyl-piperazin- 1-yl)-methyl}-benzamide; 4-([4-(3-furylmethyl)-1-piperazimyl]{3-[(methylsulfonyl)amino]phenyl }-N, N-diisopropyl- benzamide; 4-{(3-aminophenyl)[4-(3-thienylmethyl)-1-piperazinylJmethyl }-N,N-diethylbenzamide; 4-[(3-aminophenyl)(4-benzyl-1-piperazinyl)methyl]-N,N-diethylbenzamide, and ~ 4-((4-benzyl-1-piperazinyl){3-[(methylsulfonyl)aminolphenyl } methyl)-N,N- diethylbenzamide.
7. A compound according to any of the preceding claims, in form of its hydrochloride, dihydrochloride, sulfate, tartrate, ditrifluoroacetate or citrate salts.
8. A process for preparing a compound of formula I wherein R* is -OH, comprising reacting a compound of the general formula II oO R2 R3 Tod R? RA Br J wherein R? and R® are as defined in claim 1 and R*is OMe, with Boc-piperazine in : acetonitrile in the presence of triethylamine under standard conditions, followed by removal of } the Boc protection group under standard conditions to give a compound of the Formula III
O R “N R3 R? OMe : . 4 ) N H Im which is thereafter alkylated under reductive conditions with a compound of the Formula R’- CHO, followed by cleavage of the methyl ether using BBr3 in dichloromethane to give a compound of the Formula I wherein R* is —OH.
9. A process for preparing a compound of formula I wherein R* is -NHa, comprising reacting a compound of the general formula IV ~~. Oo R2 R3 TOO Br Iv wherein R? and R’ are as defined in claim 1 and R* is NO,, with Boc-piperazine in acetonitrile : in the presence of triethylamine under standard conditions, followed by removal of the Boc protection group under standard conditions to give a compound of the Formula V 0 Tog R2 ~~ NG, 0) N H v which is thereafter alkylated under reductive conditions with a compound of the Formula R'- CHO, followed by reduction of the nitro group using hydrogen and palladium on charcoal to - give a compound of the Formula I wherein R? is ~NHj.
10. A process for preparing a compound of formula I wherein R* is -NHSO,R’, comprising reacting a compound of the general formula VI 0 R2 3 ~N R NYS R? R4 Br VI wherein R* and R® are as defined in claim 1 and R*is NO», with Boc-piperazine in acetonitrile in the presence of triethylamine under standard conditions, followed reduction of the nitro group by hydrogenolysis using palladium on charcoal as the catalyst, metanesulphonylation using methanesulphonylanhydride in dichloromethane in the presence of triethylamine, and 1s thereafter removal of the Boc protection group under standard conditions to give a compound of the Formula VII o
2 . Ra R® R? NHSO,CH, 8 N H VII which is thereafter alkylated under reductive conditions with a compound of the Formula R'- CHO, followed by reduction of the nitro group using hydrogen and palladium on charcoal to give a compound of the Formula I wherein R* is -NHSO,R® .
PCT/SE02/00956
11. A compound according to any of claims 1-7 for use in therapy.
12. Use of a compound according to formula I of claim 1 for the manufacture of a medicament for use in the treatment of pain, anxiety or functional gastrointestinal disorders.
13. A pharmaceutical composition comprising a compound of the formula I according to claim 1 as an active ingredient, together with a pharmacologically and pharmaceutically acceptable carrier.
14. A method for the treatment of pain, whereby an effective amount of a compound of the formula I according to claim 1 is administered to a subject in need of pain management.
15. A substance or composition for use in a method for the treatment of functional gastrointestinal disorders, said substance or composition comprising a compound of the formula I according to claim 1, and said method comprising administering an effective amount of said substance or composition to a subject suffering from said functional gastrointestinal disorder.
16. Use of a compound according to any of claims 1-7 in the manufacture of a medicament for use in treatment.
17. A substance or composition for use in a method for the treatment of pain, said substance or composition comprising a compound of the formula I according to claim 1 and said method comprising administering an effective amount of said substance or composition to a subject in need of pain management.
18. A compound according to claim 1, substantially as herein described and illustrated.
19. A process according to any one of claims 8 to 10, substantially as herein described and illustrated. AMENDED SHEET
} 36 PCT/SE02/00956
20. A substance or composition for use in a method of treatment according to any one of claims 11, or 15, or 17, substantially as herein described and illustrated.
21. Use according to claim 12, or claim 16, substantially as herein described and illustrated. 22, A composition according to claim 13, substantially as herein described and illustrated.
23. A method according to claim 14, substantially as herein described and illustrated.
24. A new compound, a new process for preparing a compound, a substance or composition for a new use in a method of treatment, a new use of a compound of any of claims 1-7, a new composition, or a new non-therapeutic method of treatment, substantially as herein described. AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0101772A SE0101772D0 (en) | 2001-05-18 | 2001-05-18 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200308638B true ZA200308638B (en) | 2005-02-07 |
Family
ID=20284175
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200308638A ZA200308638B (en) | 2001-05-18 | 2003-11-05 | 4(Phenyl-piperazinyl-methyl)benzamide derivatives and their use for the treatment of pain anxiety or gastrointestinal disorders. |
Country Status (3)
Country | Link |
---|---|
SE (1) | SE0101772D0 (en) |
UA (1) | UA77672C2 (en) |
ZA (1) | ZA200308638B (en) |
-
2001
- 2001-05-18 SE SE0101772A patent/SE0101772D0/en unknown
-
2002
- 2002-05-16 UA UA2003109695A patent/UA77672C2/en unknown
-
2003
- 2003-11-05 ZA ZA200308638A patent/ZA200308638B/en unknown
Also Published As
Publication number | Publication date |
---|---|
SE0101772D0 (en) | 2001-05-18 |
UA77672C2 (en) | 2007-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2004213616B2 (en) | A process of preparing imatinib | |
JP6621329B2 (en) | Novel compounds, their synthesis and their use | |
JP6535687B2 (en) | Alkyl and aryl derivatives of 1-oxa-4,9-diazaspiroundecane compounds with diverse activity against pain | |
CZ20011760A3 (en) | Pyrrolidine derivatives functioning as CCR-3 receptor antagonists | |
EP2373629B1 (en) | Compounds for treating cancer | |
JP4861979B2 (en) | Tetrahydroisoquinoline sulfonamide derivatives, their preparation and use in the treatment | |
JP2006514656A (en) | CB1 / CB2 receptor ligand and its use in the treatment of pain | |
CA2446326A1 (en) | 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | |
JP6061948B2 (en) | 1-Substituted 4-arylpiperazines as kappa opioid receptor antagonists | |
MXPA04005999A (en) | Piperazine derivative. | |
TWI481605B (en) | 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands | |
ZA200204256B (en) | Novel compounds. | |
JPWO2020132014A5 (en) | ||
FI97617B (en) | Process for the preparation of novel therapeutically useful N-arylpiperazine acetamide derivatives | |
ZA200204257B (en) | Novel compounds. | |
JPH02229148A (en) | Remedy | |
BG98812A (en) | Therapeutical compounds | |
ZA200308634B (en) | 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain anxiety or gastrointestinal disorders. | |
US5051422A (en) | 2-substituted-1(4)-aryl piperazines and the process for their preparation | |
ZA200308638B (en) | 4(Phenyl-piperazinyl-methyl)benzamide derivatives and their use for the treatment of pain anxiety or gastrointestinal disorders. | |
ZA200308641B (en) | 4-(Phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders. | |
ZA200308637B (en) | 4-[Phenyl-(piperidin-4-yl)-amino]-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders. | |
RU2822624C1 (en) | 1,3,4-oxadiazole derivatives as histone deacetylase 6 inhibitor and pharmaceutical composition containing thereof | |
JPH07252218A (en) | Pyrrolidinone derivative | |
JP2003535845A (en) | Propanolaminotetralins, their preparation and compositions containing them |